Drugmakers Need to Break Their Blockbuster Addiction

The industry would be wise to diversfy its revenue streams. Otherwise, the pressures on it to ease up on prices will only intensify

By David Shook

To continue reading this article you must be a Bloomberg Professional Service Subscriber.